Institution
Edinburgh Cancer Research Centre
Facility•Edinburgh, United Kingdom•
About: Edinburgh Cancer Research Centre is a facility organization based out in Edinburgh, United Kingdom. It is known for research contribution in the topics: Breast cancer & Cancer. The organization has 453 authors who have published 1013 publications receiving 67228 citations. The organization is also known as: Edinburgh Cancer Research UK Centre & University of Edinburgh Cancer Research Centre.
Topics: Breast cancer, Cancer, Population, Proto-oncogene tyrosine-protein kinase Src, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: It is shown that the interaction between human pVHL and a specific domain of the HIF-1α subunit is regulated through hydroxylation of a proline residue by an enzyme the authors have termed Hif-α prolyl-hydroxylase (HIF-PH).
Abstract: Hypoxia-inducible factor (HIF) is a transcriptional complex that plays a central role in the regulation of gene expression by oxygen. In oxygenated and iron replete cells, HIF-alpha subunits are rapidly destroyed by a mechanism that involves ubiquitylation by the von Hippel-Lindau tumor suppressor (pVHL) E3 ligase complex. This process is suppressed by hypoxia and iron chelation, allowing transcriptional activation. Here we show that the interaction between human pVHL and a specific domain of the HIF-1alpha subunit is regulated through hydroxylation of a proline residue (HIF-1alpha P564) by an enzyme we have termed HIF-alpha prolyl-hydroxylase (HIF-PH). An absolute requirement for dioxygen as a cosubstrate and iron as cofactor suggests that HIF-PH functions directly as a cellular oxygen sensor.
5,186 citations
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Abstract: A b s t r ac t The interim analysis of time to progression met specified criteria for early reporting on the basis of superiority in the combination-therapy group. The hazard ratio for the independently assessed time to progression was 0.49 (95% confidence interval, 0.34 to 0.71; P<0.001), with 49 events in the combination-therapy group and 72 events in the monotherapy group. The median time to progression was 8.4 months in the combination-therapy group as compared with 4.4 months in the monotherapy group. This improvement was achieved without an increase in serious toxic effects or symptomatic cardiac events. Conclusions Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2- positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. (ClinicalTrials.gov number, NCT00078572.)
3,149 citations
Food and Drug Administration1, Université Bordeaux Segalen2, Edinburgh Cancer Research Centre3, MedStar Washington Hospital Center4, European Organisation for Research and Treatment of Cancer5, Memorial Sloan Kettering Cancer Center6, University of North Carolina at Chapel Hill7, University of Texas MD Anderson Cancer Center8, Virginia Commonwealth University9, Ludwig Maximilian University of Munich10
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
2,793 citations
Book•
14 Mar 1996TL;DR: The Oxford Textbook of Palliative Medicine 4Ed - Libros de Medicina - Oncologia general - 95,00 as mentioned in this paper, with a focus on cancer.
Abstract: Oxford Textbook of Palliative Medicine 4Ed - Libros de Medicina - Oncologia general - 95,00
1,784 citations
St James's University Hospital1, University College London2, Paris Descartes University3, Oslo University Hospital4, University of British Columbia5, University of Valencia6, Charité7, University of Duisburg-Essen8, Edinburgh Cancer Research Centre9, University of Copenhagen10, University of Helsinki11, Laval University12, University of Leeds13, Medical Research Council14, Cambridge University Hospitals NHS Foundation Trust15, Princess Margaret Cancer Centre16
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Abstract: A B S T R AC T Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. Methods We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 addi tional cycles or until progression of disease. Outcome measures included progressionfree survival, first analyzed per protocol and then updated, and interim overall survival. Results
1,752 citations
Authors
Showing all 466 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| David Cameron | 154 | 1586 | 126067 |
| Peter Hall | 132 | 1640 | 85019 |
| Paul Brennan | 132 | 1221 | 72748 |
| Ian Tomlinson | 119 | 607 | 55576 |
| Richard Gray | 109 | 808 | 78580 |
| Gordon D Murray | 107 | 393 | 47440 |
| Kathleen I. Pritchard | 96 | 534 | 55670 |
| Kenneth C. H. Fearon | 91 | 306 | 37759 |
| Michael Sharpe | 84 | 417 | 30546 |
| Malcolm G. Dunlop | 81 | 322 | 30814 |
| John M. S. Bartlett | 74 | 322 | 38957 |
| Paul Martin | 72 | 237 | 26916 |
| Margaret C. Frame | 71 | 165 | 17608 |
| Martin Lee | 71 | 532 | 23444 |
| John F. Smyth | 65 | 301 | 13206 |